Clinically, certain patients with IFS or other sarcomas with NTRK rearrangement may now benefit from targeted therapy with the TRK inhibitor Larotrectinib, making the accurate diagnosis of these neoplasms of further importance [36,37]. The gene discussed is NTRK1; the disease is neoplasm.